- Published on
Infectious Disease – Diarrhea and Fever
FUNDAMENTALS AND DESCRIPTION
Diarrhea is clinically defined as an elevation in daily stool weight above 200 grams and more broadly characterized as the occurrence of three or more loose stools daily. Diarrhea is classified as acute when it persists for less than 14 days and as chronic when it endures for more than 4 weeks. An inflammatory diarrheal syndrome is defined by frequent, small-volume feces that may be mucoid, bloody, or both. It may be associated with tenesmus, fever, or intense stomach pain. The defining characteristic of inflammatory diarrheas is the presence of leukocytes in the feces. A noninflammatory diarrheal condition is defined by the presence of voluminous watery stools (>1 L/d) that lack blood, pus, significant abdominal pain, or fever.
Epidemiology: Incidence Approximately 200 to 375 million instances of severe diarrhea transpire annually in the United States. Approximately 38 million of these events are ascribed to a recognized pathogen (bacteria, parasite, or virus). Foodborne transmission is responsible for approximately 36% of diarrheal diseases caused by identified pathogens. In 2007, of the 9 bacterial enteropathogens monitored by FoodNet, the predominant causes were non-typhoid salmonella (14.86 cases per 100,000 population), campylobacter (12.78), shigella (6.24), cryptosporidium (2.67), and Shiga toxin-producing E. coli (STEC) O157 (1.19). • The prevalence of bacterial diarrhea attributed to salmonella, campylobacter, and yersinia is greatest in infants under one year of age. The prevalence of post-diarrheal hemolytic uremic syndrome (HUS) in the United States is 0.65 instances per 100,000 individuals, with the highest frequency observed in children under five years of age. • Traveler's diarrhea impacts 20–60% of global travelers.
RISK FACTORS • Ingesting uncooked eggs, pork, shellfish, poultry, or unpasteurized dairy products. • Consuming unpurified water from streams or rivers. Conditions linked to heightened illness severity or increased susceptibility to specific pathogens encompass HIV infection, immunosuppressive therapies (such as glucocorticoids, TNF inhibitors, and chemotherapy), recent antibiotic administration, hepatic disease, neutropenia, malnutrition, zinc deficiency, and IgA deficiency. • Oral-anal sexual intercourse • Antibiotic exposure is a risk factor for C. difficile-associated diarrhea.
GENERAL PREVENTION
• Cleanse hands with soap prior to consuming or preparing food. • Refrain from ingesting raw or undercooked eggs, poultry, meat, fish, and seafood. • Avoid unpasteurized dairy products. • Do not consume untreated stream or river water. • When traveling, eschew tap water and ice in regions with potentially contaminated water. • Vaccines are accessible to prevent Salmonella typhi related to international travel. Refer to the CDC website for recommended immunizations according to your destination (http://www.cdc.gov/). The Advisory Committee on Immunization Practices recommends the rotavirus vaccine for infants in the United States. CAUSES Bacteria include Campylobacter, Salmonella species, E. coli (a. Enterotoxigenic [ETEC], b. Enteropathogenic [EPEC], c. Enteroinvasive [EIEC], d. Shiga toxin-producing [STEC] including E. coli O157:H7, and e. Enteroaggregative [EAEC]), Shigella species, Yersinia enterocolitica, Clostridium difficile, Vibrio cholera, Vibrio parahaemolyticus, Aeromonas species, and Plesiomonas shigelloides. • Viruses (Rotavirus, human caliciviruses including noroviruses, Adenovirus, and Cytomegalovirus) • Parasites (Giardia intestinalis, Cryptosporidium parvum, Entamoeba histolytica, Cyclospora cayetanensis, Isospora belli, and Strongyloides stercoralis) • Toxin-mediated diarrhea (Staphylococcus aureus, Bacillus cereus, and Clostridium perfringens)
DIAGNOSIS HISTORY
A comprehensive medical history and physical examination are crucial for identifying the potential cause, severity, and existence of problems. • Inquire about recent travel, dietary habits, antibiotic consumption, sexual activity, attendance at day-care facilities, other illnesses, outbreaks, and seasonal factors. • Ascertain the frequency, duration, and nature of diarrhea (e.g., watery, bloody, etc.). • Infectious diarrhea may be accompanied by fever, chills, vomiting, nausea, stomach discomfort, and tenesmus. A history of dizziness, syncope, or presyncope suggests volume depletion. Bloody stools (dysentery) indicate the presence of an invasive infection, including Shigella, Salmonella, Campylobacter, Shiga toxin-producing E. coli (notably in the absence of fever), or Yersinia. Shiga toxin-producing E. coli, particularly O157:H7, induces watery diarrhea that progresses to bloody diarrhea and is linked to the consumption of contaminated beef or produce in around fifty percent of cases. Fever is frequently absent. Yersinia and Salmonella can infect the terminal ileum and cecum, presenting with right lower quadrant pain and tenderness indicative of acute appendicitis. • Watery diarrhea is clinically ambiguous. Gastroenteritis resulting from an enterotoxin (food poisoning) may be attributed to S. aureus, B. cereus, or C. perfringens. These instances may manifest with isolated vomiting (S. aureus or C. perfringens) or watery diarrhea (B. cereus or C. perfringens). Fever is typically absent. The incubation period is brief (2–7 hours for S. aureus; 8–14 hours for C. perfringens; C. perfringens may exhibit either duration) and the overall duration is limited. Extraintestinal signs, like arthritis, dermatological diseases, or eye problems, indicate the presence of inflammatory bowel disease. • The cause of recent overseas travel is contingent upon the place, environment, and season. The predominant pathogens comprise enterotoxigenic E. coli, enteroaggregative E. coli, Campylobacter, Salmonella, and norovirus. The CDC Travelers' Health website or other travel medicine resources can assist in diagnostic evaluation.
PHYSICAL EXAMINATION • Evaluate blood pressure, heart rate, respiration rate, temperature, and mental status to determine the severity. • Assess for indicators of dehydration such as xerostomia, impaired skin turgor, enophthalmos, reduced capillary refill time, low jugular venous pressure, or orthostatic hypotension. • Examine for abdominal discomfort, manifestations of peritonitis (guarding, rebound tenderness), hepatomegaly, and splenomegaly.
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory Initial Assessments
• The indications for diagnostic testing encompass the following: Fever, systemic sickness, hematochezia, dehydration, a confirmed or suspected outbreak of foodborne illness, recent international travel, immunosuppression, or recent antibiotic administration. Submit stool specimen for culture analysis. In the majority of microbiology laboratories, stool samples submitted for the culture of enteric pathogens will be analyzed for Shigella, Salmonella, and Campylobacter. Consequently, if there is a strong clinical suspicion for E. coli (STEC, ETEC, EPEC, EIEC), Yersinia, Vibrio, etc., inform the microbiology laboratory. The diagnostic yield of stool cultures varies between 1.5% and 5.6%. • In cases with bloody diarrhea, do stool cultures for Salmonella, Shigella, Campylobacter, and Shiga toxin-producing E. coli, and conduct an immunoassay for Shiga toxin. Upon isolation of E. coli, dispatch to a reference laboratory for serotyping. • In cases of recent antibiotic use, hospitalization, daycare exposure, or chemotherapy, stool specimens should be analyzed for C. difficile toxins A and B. For diarrhea lasting over 7 days, collect numerous stool specimens for ova and parasite analysis, specifically targeting Giardia, Cryptosporidium, Isospora belli, and Cyclospora. Evaluate noninfectious etiology. In individuals with AIDS or immunosuppression, further test for microsporidia, Mycobacterium avium.
complex, and CMV. • A positive fecal test for polymorphonuclear cells indicates inflammatory diarrhea. Subsequent Actions & Unique Considerations In cases of dehydration or severe sickness, assess serum electrolytes, renal function, hepatic function, total blood count, and blood cultures. Imaging If the diagnosis is ambiguous, accompanied by critical illness, significant abdominal pain, or signs of peritonitis, consider performing a CT scan with both oral and intravenous contrast. Diagnostic Procedures and Additional Methods For additional assessment, contemplate upper gastrointestinal endoscopy or colonoscopy accompanied by diagnostic biopsies.
DIFFERENTIAL DIAGNOSIS • Acute inflammatory diarrheal syndrome may also arise from noninfectious causes, including ulcerative colitis, Crohn’s disease, radiation or ischemic colitis, partial bowel obstruction, diverticulitis, laxative abuse, rectosigmoid abscess, Whipple’s disease, pernicious anemia, diabetes, malabsorption, scleroderma, or celiac sprue. Diarrhea and fever may also arise from infections beyond the gastrointestinal tract, such as malaria or sepsis.
THERAPY PHARMACEUTICALS
The major elements of treatment consist of fluids and antibiotics. Oral rehydration constitutes the most suitable and cost-effective management strategy for both developing and wealthy nations. Intravenous volume repletion is warranted in cases of severe dehydration or significant electrolyte imbalance. The rice-based oral solution is more effective in adults and children suffering from cholera. Antimicrobial therapy is warranted in cases of severe infection and is advised for persistent gastroenteritis, individuals over 65 years of age, immunocompromised patients, those with prosthetic devices, and in instances of invasive infections, excluding those caused by Shiga toxin-producing E. coli. Empiric therapy: For febrile community-acquired invasive diarrhea or moderate to severe traveler's diarrhea, administer ciprofloxacin 500 mg twice day or levofloxacin 500 mg daily while awaiting stool investigations, unless Shiga toxin-producing E. coli is suspected. In the event of recent travel to Southeast Asia, investigate fluoroquinolone-resistant Campylobacter. If there has been recent antibiotic usage or nosocomial diarrhea, administer metronidazole or vancomycin while awaiting assay results for C. difficile toxin.
Chosen pathogens and their treatment: • Salmonella (non-typhi species) — Bacteremia manifests in 2–8% of cases. Administer treatment for severe disease in individuals under 12 months, over 50 years, with valvular disease, severe atherosclerosis, prosthetic devices, cancer, HIV, uremia, sickle cell disease, and other immunocompromised conditions. Ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg orally once daily for 5 to 7 days. If susceptible, provide TMP-SMX DS twice daily for 5–7 days, or ceftriaxone 2 g IV/IM daily for 5–7 days. Administer treatment for 14 days if the individual is immunocompromised. Antibiotics may augment shedding. • Shigellosis – provide ciprofloxacin 500 mg orally twice daily, or levofloxacin 500 mg once daily for 3 days, or if susceptible, TMP-SMX DS twice daily for 3 days. Administer treatment for 7 to 10 days in cases of severe disease or in immunocompromised individuals. • Campylobacter – provide erythromycin 500 mg bi-daily for a duration of 5 days. Significant fluoroquinolone resistance, particularly in Southeast Asia. • Escherichia coli, Shiga toxin-producing (STEC) – Avoid antibiotics as they may elevate the risk of hemolytic uremic syndrome (HUS).
Auxiliary care. • E. coli (ETEC, EPEC, EIEC) – provide ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg daily for a duration of 3 days. Administer TMP-SMX DS bi-daily for three days if susceptible. • Yersinia – antibiotics are generally unnecessary. For severe infections or immunocompromised patients, administer doxycycline in conjunction with an aminoglycoside, fluoroquinolone, or TMP-SMX. • C. difficile – discontinue superfluous antibiotics and use metronidazole 500 mg three times daily for moderate cases or vancomycin 125 mg four times daily for 10–14 days. Kindly refer to the pertinent subject. • Cholera: Fluid replenishment is essential. Examine local susceptibilities. Treatment options include doxycycline, tetracycline, TMP-SMX, or fluoroquinolone. Amebiasis: Administer metronidazole 750 mg three times daily for five days (ten days in severe cases), followed by paromomycin 500 mg three times daily for seven days, or iodoquinol 650 mg three times daily for twenty days. • Giardiasis: Metronidazole 250–750 mg administered thrice day for 7–10 days or tinidazole 2 g as a single dose • Cyclospora & Isospora – Administer TMP-SMX 1 DS bi-daily for a duration of 7–10 days. If immunocompromised, prolong treatment and contemplate suppression.
SUPPLEMENTARY THERAPY
Comprehensive Strategies • The majority of mild instances are self-resolving. Symptomatic treatment encompasses water and anti-motility medicines, including loperamide. Loperamide is the preferred antidiarrheal medication for people experiencing mild to moderate diarrhea without hematochezia. It is contraindicated in instances of severe inflammatory or bloody diarrhea, C. difficile infection, and in children under 2 years of age. Bismuth salicylate functions as an antisecretory agent and can diminish stool output in both children and adults. Concerns for Referral • In instances of severe or persistent diarrhea of indeterminate origin, consider consulting gastroenterology and/or infectious diseases specialists. • Document instances of Salmonella species, Shigella, Campylobacter, E. coli, cholera, cryptosporidiosis, cyclosporiasis, Vibrio species, and any suspected or confirmed outbreaks.
INPATIENT CONSIDERATIONS
Preliminary Stabilization Immediate rehydration and empirical antibiotics are necessary in cases of severe acute diarrhea accompanied by systemic toxicity. Criteria for Admission Admit individuals exhibiting severe dehydration or an inability to sustain fluid intake. Intravenous Fluids Intravenous volume repletion is warranted in cases of severe dehydration or when the patient exhibits changed mental status. Criteria for Discharge Patients may be discharged after fevers diminish for over 24 hours, vital signs stabilize, and the patient can sustain sufficient fluid and food intake.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Evaluate and administer treatment to families exhibiting like symptoms.
DIET • Nutritional intake may commence four hours following the initiation of oral or intravenous hydration. • Provide regular, little portions of easily digestible food. Avoid hyperosmolar fruit juices, as they may worsen diarrhea.
INFORMATION FOR PATIENTS
Instruct patients on general food safety practices and methods to prevent foodborne infections, particularly during travel. OUTLOOK Gastrointestinal diseases account for about 900,000 hospitalizations and 6,000 fatalities in the United States each year.
COMPLICATIONS
Complications encompass dehydration, electrolyte imbalances, bacteremia and sepsis, malnutrition and vitamin deficiency, hemolytic uremic syndrome (HUS), and systemic amebiasis.
FUNDAMENTALS AND DESCRIPTION
Diarrhea is clinically defined as an elevation in daily stool weight above 200 grams and more broadly characterized as the occurrence of three or more loose stools daily. Diarrhea is classified as acute when it persists for less than 14 days and as chronic when it endures for more than 4 weeks. An inflammatory diarrheal syndrome is defined by frequent, small-volume feces that may be mucoid, bloody, or both. It may be associated with tenesmus, fever, or intense stomach pain. The defining characteristic of inflammatory diarrheas is the presence of leukocytes in the feces. A noninflammatory diarrheal condition is defined by the presence of voluminous watery stools (>1 L/d) that lack blood, pus, significant abdominal pain, or fever.
Epidemiology: Incidence Approximately 200 to 375 million instances of severe diarrhea transpire annually in the United States. Approximately 38 million of these events are ascribed to a recognized pathogen (bacteria, parasite, or virus). Foodborne transmission is responsible for approximately 36% of diarrheal diseases caused by identified pathogens. In 2007, of the 9 bacterial enteropathogens monitored by FoodNet, the predominant causes were non-typhoid salmonella (14.86 cases per 100,000 population), campylobacter (12.78), shigella (6.24), cryptosporidium (2.67), and Shiga toxin-producing E. coli (STEC) O157 (1.19). • The prevalence of bacterial diarrhea attributed to salmonella, campylobacter, and yersinia is greatest in infants under one year of age. The prevalence of post-diarrheal hemolytic uremic syndrome (HUS) in the United States is 0.65 instances per 100,000 individuals, with the highest frequency observed in children under five years of age. • Traveler's diarrhea impacts 20–60% of global travelers.
RISK FACTORS • Ingesting uncooked eggs, pork, shellfish, poultry, or unpasteurized dairy products. • Consuming unpurified water from streams or rivers. Conditions linked to heightened illness severity or increased susceptibility to specific pathogens encompass HIV infection, immunosuppressive therapies (such as glucocorticoids, TNF inhibitors, and chemotherapy), recent antibiotic administration, hepatic disease, neutropenia, malnutrition, zinc deficiency, and IgA deficiency. • Oral-anal sexual intercourse • Antibiotic exposure is a risk factor for C. difficile-associated diarrhea.
GENERAL PREVENTION
• Cleanse hands with soap prior to consuming or preparing food. • Refrain from ingesting raw or undercooked eggs, poultry, meat, fish, and seafood. • Avoid unpasteurized dairy products. • Do not consume untreated stream or river water. • When traveling, eschew tap water and ice in regions with potentially contaminated water. • Vaccines are accessible to prevent Salmonella typhi related to international travel. Refer to the CDC website for recommended immunizations according to your destination (http://www.cdc.gov/). The Advisory Committee on Immunization Practices recommends the rotavirus vaccine for infants in the United States. CAUSES Bacteria include Campylobacter, Salmonella species, E. coli (a. Enterotoxigenic [ETEC], b. Enteropathogenic [EPEC], c. Enteroinvasive [EIEC], d. Shiga toxin-producing [STEC] including E. coli O157:H7, and e. Enteroaggregative [EAEC]), Shigella species, Yersinia enterocolitica, Clostridium difficile, Vibrio cholera, Vibrio parahaemolyticus, Aeromonas species, and Plesiomonas shigelloides. • Viruses (Rotavirus, human caliciviruses including noroviruses, Adenovirus, and Cytomegalovirus) • Parasites (Giardia intestinalis, Cryptosporidium parvum, Entamoeba histolytica, Cyclospora cayetanensis, Isospora belli, and Strongyloides stercoralis) • Toxin-mediated diarrhea (Staphylococcus aureus, Bacillus cereus, and Clostridium perfringens)
DIAGNOSIS HISTORY
A comprehensive medical history and physical examination are crucial for identifying the potential cause, severity, and existence of problems. • Inquire about recent travel, dietary habits, antibiotic consumption, sexual activity, attendance at day-care facilities, other illnesses, outbreaks, and seasonal factors. • Ascertain the frequency, duration, and nature of diarrhea (e.g., watery, bloody, etc.). • Infectious diarrhea may be accompanied by fever, chills, vomiting, nausea, stomach discomfort, and tenesmus. A history of dizziness, syncope, or presyncope suggests volume depletion. Bloody stools (dysentery) indicate the presence of an invasive infection, including Shigella, Salmonella, Campylobacter, Shiga toxin-producing E. coli (notably in the absence of fever), or Yersinia. Shiga toxin-producing E. coli, particularly O157:H7, induces watery diarrhea that progresses to bloody diarrhea and is linked to the consumption of contaminated beef or produce in around fifty percent of cases. Fever is frequently absent. Yersinia and Salmonella can infect the terminal ileum and cecum, presenting with right lower quadrant pain and tenderness indicative of acute appendicitis. • Watery diarrhea is clinically ambiguous. Gastroenteritis resulting from an enterotoxin (food poisoning) may be attributed to S. aureus, B. cereus, or C. perfringens. These instances may manifest with isolated vomiting (S. aureus or C. perfringens) or watery diarrhea (B. cereus or C. perfringens). Fever is typically absent. The incubation period is brief (2–7 hours for S. aureus; 8–14 hours for C. perfringens; C. perfringens may exhibit either duration) and the overall duration is limited. Extraintestinal signs, like arthritis, dermatological diseases, or eye problems, indicate the presence of inflammatory bowel disease. • The cause of recent overseas travel is contingent upon the place, environment, and season. The predominant pathogens comprise enterotoxigenic E. coli, enteroaggregative E. coli, Campylobacter, Salmonella, and norovirus. The CDC Travelers' Health website or other travel medicine resources can assist in diagnostic evaluation.
PHYSICAL EXAMINATION • Evaluate blood pressure, heart rate, respiration rate, temperature, and mental status to determine the severity. • Assess for indicators of dehydration such as xerostomia, impaired skin turgor, enophthalmos, reduced capillary refill time, low jugular venous pressure, or orthostatic hypotension. • Examine for abdominal discomfort, manifestations of peritonitis (guarding, rebound tenderness), hepatomegaly, and splenomegaly.
DIAGNOSTIC TESTS AND INTERPRETATION
Laboratory Initial Assessments
• The indications for diagnostic testing encompass the following: Fever, systemic sickness, hematochezia, dehydration, a confirmed or suspected outbreak of foodborne illness, recent international travel, immunosuppression, or recent antibiotic administration. Submit stool specimen for culture analysis. In the majority of microbiology laboratories, stool samples submitted for the culture of enteric pathogens will be analyzed for Shigella, Salmonella, and Campylobacter. Consequently, if there is a strong clinical suspicion for E. coli (STEC, ETEC, EPEC, EIEC), Yersinia, Vibrio, etc., inform the microbiology laboratory. The diagnostic yield of stool cultures varies between 1.5% and 5.6%. • In cases with bloody diarrhea, do stool cultures for Salmonella, Shigella, Campylobacter, and Shiga toxin-producing E. coli, and conduct an immunoassay for Shiga toxin. Upon isolation of E. coli, dispatch to a reference laboratory for serotyping. • In cases of recent antibiotic use, hospitalization, daycare exposure, or chemotherapy, stool specimens should be analyzed for C. difficile toxins A and B. For diarrhea lasting over 7 days, collect numerous stool specimens for ova and parasite analysis, specifically targeting Giardia, Cryptosporidium, Isospora belli, and Cyclospora. Evaluate noninfectious etiology. In individuals with AIDS or immunosuppression, further test for microsporidia, Mycobacterium avium.
complex, and CMV. • A positive fecal test for polymorphonuclear cells indicates inflammatory diarrhea. Subsequent Actions & Unique Considerations In cases of dehydration or severe sickness, assess serum electrolytes, renal function, hepatic function, total blood count, and blood cultures. Imaging If the diagnosis is ambiguous, accompanied by critical illness, significant abdominal pain, or signs of peritonitis, consider performing a CT scan with both oral and intravenous contrast. Diagnostic Procedures and Additional Methods For additional assessment, contemplate upper gastrointestinal endoscopy or colonoscopy accompanied by diagnostic biopsies.
DIFFERENTIAL DIAGNOSIS • Acute inflammatory diarrheal syndrome may also arise from noninfectious causes, including ulcerative colitis, Crohn’s disease, radiation or ischemic colitis, partial bowel obstruction, diverticulitis, laxative abuse, rectosigmoid abscess, Whipple’s disease, pernicious anemia, diabetes, malabsorption, scleroderma, or celiac sprue. Diarrhea and fever may also arise from infections beyond the gastrointestinal tract, such as malaria or sepsis.
THERAPY PHARMACEUTICALS
The major elements of treatment consist of fluids and antibiotics. Oral rehydration constitutes the most suitable and cost-effective management strategy for both developing and wealthy nations. Intravenous volume repletion is warranted in cases of severe dehydration or significant electrolyte imbalance. The rice-based oral solution is more effective in adults and children suffering from cholera. Antimicrobial therapy is warranted in cases of severe infection and is advised for persistent gastroenteritis, individuals over 65 years of age, immunocompromised patients, those with prosthetic devices, and in instances of invasive infections, excluding those caused by Shiga toxin-producing E. coli. Empiric therapy: For febrile community-acquired invasive diarrhea or moderate to severe traveler's diarrhea, administer ciprofloxacin 500 mg twice day or levofloxacin 500 mg daily while awaiting stool investigations, unless Shiga toxin-producing E. coli is suspected. In the event of recent travel to Southeast Asia, investigate fluoroquinolone-resistant Campylobacter. If there has been recent antibiotic usage or nosocomial diarrhea, administer metronidazole or vancomycin while awaiting assay results for C. difficile toxin.
Chosen pathogens and their treatment: • Salmonella (non-typhi species) — Bacteremia manifests in 2–8% of cases. Administer treatment for severe disease in individuals under 12 months, over 50 years, with valvular disease, severe atherosclerosis, prosthetic devices, cancer, HIV, uremia, sickle cell disease, and other immunocompromised conditions. Ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg orally once daily for 5 to 7 days. If susceptible, provide TMP-SMX DS twice daily for 5–7 days, or ceftriaxone 2 g IV/IM daily for 5–7 days. Administer treatment for 14 days if the individual is immunocompromised. Antibiotics may augment shedding. • Shigellosis – provide ciprofloxacin 500 mg orally twice daily, or levofloxacin 500 mg once daily for 3 days, or if susceptible, TMP-SMX DS twice daily for 3 days. Administer treatment for 7 to 10 days in cases of severe disease or in immunocompromised individuals. • Campylobacter – provide erythromycin 500 mg bi-daily for a duration of 5 days. Significant fluoroquinolone resistance, particularly in Southeast Asia. • Escherichia coli, Shiga toxin-producing (STEC) – Avoid antibiotics as they may elevate the risk of hemolytic uremic syndrome (HUS).
Auxiliary care. • E. coli (ETEC, EPEC, EIEC) – provide ciprofloxacin 500 mg orally twice daily or levofloxacin 500 mg daily for a duration of 3 days. Administer TMP-SMX DS bi-daily for three days if susceptible. • Yersinia – antibiotics are generally unnecessary. For severe infections or immunocompromised patients, administer doxycycline in conjunction with an aminoglycoside, fluoroquinolone, or TMP-SMX. • C. difficile – discontinue superfluous antibiotics and use metronidazole 500 mg three times daily for moderate cases or vancomycin 125 mg four times daily for 10–14 days. Kindly refer to the pertinent subject. • Cholera: Fluid replenishment is essential. Examine local susceptibilities. Treatment options include doxycycline, tetracycline, TMP-SMX, or fluoroquinolone. Amebiasis: Administer metronidazole 750 mg three times daily for five days (ten days in severe cases), followed by paromomycin 500 mg three times daily for seven days, or iodoquinol 650 mg three times daily for twenty days. • Giardiasis: Metronidazole 250–750 mg administered thrice day for 7–10 days or tinidazole 2 g as a single dose • Cyclospora & Isospora – Administer TMP-SMX 1 DS bi-daily for a duration of 7–10 days. If immunocompromised, prolong treatment and contemplate suppression.
SUPPLEMENTARY THERAPY
Comprehensive Strategies • The majority of mild instances are self-resolving. Symptomatic treatment encompasses water and anti-motility medicines, including loperamide. Loperamide is the preferred antidiarrheal medication for people experiencing mild to moderate diarrhea without hematochezia. It is contraindicated in instances of severe inflammatory or bloody diarrhea, C. difficile infection, and in children under 2 years of age. Bismuth salicylate functions as an antisecretory agent and can diminish stool output in both children and adults. Concerns for Referral • In instances of severe or persistent diarrhea of indeterminate origin, consider consulting gastroenterology and/or infectious diseases specialists. • Document instances of Salmonella species, Shigella, Campylobacter, E. coli, cholera, cryptosporidiosis, cyclosporiasis, Vibrio species, and any suspected or confirmed outbreaks.
INPATIENT CONSIDERATIONS
Preliminary Stabilization Immediate rehydration and empirical antibiotics are necessary in cases of severe acute diarrhea accompanied by systemic toxicity. Criteria for Admission Admit individuals exhibiting severe dehydration or an inability to sustain fluid intake. Intravenous Fluids Intravenous volume repletion is warranted in cases of severe dehydration or when the patient exhibits changed mental status. Criteria for Discharge Patients may be discharged after fevers diminish for over 24 hours, vital signs stabilize, and the patient can sustain sufficient fluid and food intake.
CONTINUED MANAGEMENT POST-TREATMENT SUGGESTIONS
Evaluate and administer treatment to families exhibiting like symptoms.
DIET • Nutritional intake may commence four hours following the initiation of oral or intravenous hydration. • Provide regular, little portions of easily digestible food. Avoid hyperosmolar fruit juices, as they may worsen diarrhea.
INFORMATION FOR PATIENTS
Instruct patients on general food safety practices and methods to prevent foodborne infections, particularly during travel. OUTLOOK Gastrointestinal diseases account for about 900,000 hospitalizations and 6,000 fatalities in the United States each year.
COMPLICATIONS
Complications encompass dehydration, electrolyte imbalances, bacteremia and sepsis, malnutrition and vitamin deficiency, hemolytic uremic syndrome (HUS), and systemic amebiasis.
0 Comments
